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ABSTRACT
Hyperthermia – application of supra-physiological temperatures to cells, 
tissues or organs – is a pleiotropic treatment that affects most aspects of cellular 
metabolism, but its effects on DNA are of special interest in the context of cancer 
research and treatment. Hyperthermia inhibits repair of various DNA lesions, including 
double-strand breaks (DSBs), making it a powerful radio- and chemosensitizer, with 
proven clinical efficacy in therapy of various types of cancer, including tumors of 
head and neck, bladder, breast and cervix. Among the challenges for hyperthermia-
based therapies are the transient character of its effects, the technical difficulties 
in maintaining uniformly elevated tumor temperature and the acquisition of 
thermotolerance. Approaches to reduce or eliminate these challenges could simplify 
the application of hyperthermia, boost its efficacy and improve treatment outcomes. 
Here we show that a single, short treatment with a relatively low dose of HSP90 
inhibitor Ganetespib potentiates cytotoxic as well as radio- and chemosensitizing 
effects of hyperthermia and reduces thermotolerance in cervix cancer cell lines. 
Ganetespib alone, applied at this low dose, has virtually no effect on survival of non-
heated cells. Our results thus suggest that HSP90 inhibition can be a safe, simple 
and efficient approach to improving hyperthermia treatment efficacy and reducing 
thermotolerance, paving the way for in vivo studies.
INTRODUCTION
DNA-damaging agents, such as ionizing radiation, 
topoisomerase inhibitors, DNA intercalators or cross-
linkers, are among the most effective anticancer modalities 
exploited in diverse clinically relevant therapies. However, 
the intricate DNA repair mechanisms that evolved to 
maintain the integrity of genetic information of healthy 
cells, protect DNA of cancer cells, effectively increasing 
their resistance to therapy [1].
DNA double-strand breaks (DSBs) are arguably 
the most dangerous DNA lesions induced by anticancer 
treatments. In mammalian cells, DSB repair is executed by 
two major pathways, called non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ 
is a robust and conceptually simple mechanism, active 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 57), pp: 97490-97503
                                                     Research Paper
Oncotarget97491www.impactjournals.com/oncotarget
throughout the cell cycle. The pathway involves a direct 
rejoining of the broken DNA ends, often at the cost of 
inducing nucleotide deletions or insertions [2]. In contrast 
to NHEJ, HR is a more complex and precise mechanism 
– relying on BRCA1, BRCA2 and RAD51, among other 
proteins – that can utilize an intact DNA fragment as a 
repair template [3]. The activity of HR is tightly coupled 
to cell cycle progression and limited to the S and G2 
phases of the cell cycle. Given the involvement of DSB 
repair in the resistance to DNA-damaging agents, its 
inactivation in cancer cells could increase their sensitivity 
to therapy. Despite considerable efforts, however, safe, 
potent, selective and bioavailable inhibitors of DSB repair 
have yet to emerge.
Hyperthermia – elevation of the tumor temperature 
above physiological levels, usually to 41-42.5°C – is 
a clinically applied anticancer therapy that affects 
multiple aspects of cellular metabolism, including DNA 
repair [4]. Hyperthermia is an excellent radiosensitizer 
and chemosensitizer, as demonstrated by in vitro and 
in vivo studies, as well as by randomized clinical trials 
[4–6]. One important feature of hyperthermia is that its 
application can generally be limited to the tumor volume, 
sparing the non-transformed surrounding tissues. Notably, 
hyperthermia efficiently inhibits HR, likely by inducing 
degradation of its essential protein BRCA2 [7, 8], as well 
as NHEJ, possibly in part by affecting DNA-PKcs or LIG4 
[9, 10]. This may explain how hyperthermia sensitizes 
cells to agents such as ionizing radiation or cisplatin, 
because DNA lesions induced by these agents require HR 
and NHEJ for repair.
The radiosensitizing and chemosensitizing effects of 
hyperthermia are desirable in anticancer therapies, but they 
are counteracted by chaperone proteins that protect cells 
from the effects of various forms of stress, including heat. 
Heat-shock proteins (HSPs) are a subgroup of chaperone 
proteins that strongly respond to increased temperatures 
to regulate various genes and metabolic pathways as well 
as to physically protect their client proteins from heat-
induced unfolding, inactivation and degradation [11]. One 
member of this group, HSP90, is of special interest in the 
context of cancer treatment and hyperthermia. HSP90 
is an evolutionarily conserved chaperone, crucial in 
mammalian proteostasis, with affinity for a vast number of 
client proteins [12]. Inhibition of this chaperone affects the 
stability of some essential DNA repair factors, including 
BRCA1, BRCA2, RAD51, CHK1 and DNA-PKcs [13].
Recently, we reported that inhibition of HSP90 by 
17-DMAG, the derivative of the antibiotic geldanamycin, 
can enhance the effects of hyperthermia on DSB repair, 
likely, at least in part, by stimulating hyperthermia-
induced degradation of BRCA2 [7]. 17-DMAG also 
potentiates hyperthermic sensitization of cancer cells to 
PARP1 inhibition in vitro and in vivo. Importantly, the 
drug showed only limited cytotoxicity as a single agent, 
suggesting that HSP90 inhibition could be a safe and 
effective approach to potentiate effects of hyperthermia. 
In the current study, we focus on Ganetespib, a new-
generation, more specific and well-tolerated HSP90 
inhibitor that has been extensively studied in vitro, in 
animal models and in multiple clinical trials [14]. Since 
hyperthermia is routinely applied to a subset of cervical 
cancer patients, we use two cervical cancer cell lines, SiHa 
and HeLa to show that Ganetespib enhances the induction 
of DNA damage and cell killing by hyperthermia. 
Moreover, we demonstrate that Ganetespib potentiates 
hyperthermia-induced sensitization of cervix cancer 
cells to a number of DSB-inducing agents and reduces 
hyperthermia-induced thermotolerance, suggesting that 
HSP90 inhibition could be a safe, simple and effective 
strategy to improve the outcomes of clinical treatments 
involving hyperthermia.
RESULTS
HSP90 inhibitor Ganetespib potentiates the 
inhibitory effects of hyperthermia on HR
To investigate whether Ganetespib promotes the 
inhibitory effects of hyperthermia on DSB repair, we first 
analyzed hyperthermia-induced changes in the levels of 
BRCA2 protein. As expected, we found that treatment 
for 60 min at 42°C reduced the levels of BRCA2 (Figure 
1A). Importantly, addition of Ganetespib further enhanced 
BRCA2 degradation in a dose-dependent manner. We 
found that a 1.5 h treatment with Ganetespib alone (up 
to 100 nM) had only modest effects on clonogenic cell 
survival, but this was enhanced after hyperthermia, 
at least at Ganetespib concentrations exceeding 3 nM 
(Supplementary Figure 1). We therefore decided to use 
the 30 nM concentration of Ganetespib in the subsequent 
experiments. One of the hallmarks of hyperthermia-
induced HR deficiency is a disturbed accumulation of 
RAD51 at sites of DSBs [7, 8]. Indeed, we found that 
hyperthermia temporarily abolished recruitment of RAD51 
to α-particle-induced DSBs. This effect was enhanced by 
Ganetespib, as RAD51 accumulation was impaired for 
considerably longer periods of time, in both SiHa and 
HeLa cells (Figure 1B). Treatment with Ganetespib alone 
did not affect RAD51 accumulation.
One of the most challenging aspects in successful 
clinical application of hyperthermia is the maintenance 
of the elevated tumor temperature for a sufficiently long 
period of time. Therefore, any approach to reduce the time 
required for efficient radio- or chemosensitization could 
greatly facilitate and boost hyperthermia treatments. To 
examine whether Ganetespib can shorten hyperthermia 
time required for efficient degradation of BRCA2, we 
heated HeLa and SiHa cells for 30 or 60 min, in the 
presence or absence of Ganetespib, and analyzed BRCA2 
levels. Results show that a 30 min hyperthermia + 
Ganetespib combination treatment is at least as effective 
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in reducing BRCA2 levels as a 60 min hyperthermia 
treatment without the inhibitor (Figure 1C). In summary, 
these results confirm that Ganetespib can potentiate the 
inhibitory effects of hyperthermia on HR in cervical 
cancer cells in vitro.
Inhibition of HSP90 enhances induction of DNA 
damage by hyperthermia
Hyperthermia has been suggested to induce DSBs 
in at least two ways [15]. First, it has been speculated 
that the elevated temperature induces damage directly, 
as heating leads to the focal accumulation of some repair 
factors, which are considered to mark sites of ongoing 
DSB repair [16, 17]. Second, hyperthermia has been 
suggested to stabilize the topoisomerase 1 (TOP1)-DNA 
cleavage complexes, which may lead to DSB formation 
in the next S-phase, when replication forks collide with 
single-stranded breaks (SSBs) induced by removal of 
the TOP1 [18]. To examine whether HSP90 inhibition 
can potentiate these effects as well, we first analyzed the 
induction of γH2AX foci at various time points (up to 48 
h after hyperthermia treatment). We observed, in both 
cell lines, that hyperthermia led to increased frequencies 
Figure 1: HSP90 inhibitor Ganetespib potentiates the effects of hyperthermia (HT) on HR. (A) SiHa cells were incubated 
with the indicated concentrations of Ganetespib (HSP90-i) for 30 min at 37°C, then for an additional hour at 37 or 42°C. Next, cells were 
lysed and lysates were analyzed by western blotting, using antibodies against BRCA2 and Cyclin A (loading control). (B) Cells were 
treated as in (A), except Ganetespib was used at a concentration of 30 nM. At the indicated time after treatment, cells were irradiated with 
α-particles, fixed 30 min later and stained using antibodies against γH2AX (red) and RAD51 (green). The pictures are representative for 
cells irradiated 6 h after the treatment. The graphs show average percentage of cells containing tracks of γH2AX foci that were also positive 
for RAD51. (C) Cells were treated and analyzed as in (A), except the duration of incubation at elevated temperature was 0, 30 or 60 min. 
Equal sample loading was confirmed by probing for ORC2.
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of foci-containing cells immediately after treatment, and 
that these frequencies diminished at later time points 
(Figure 2A). After treatment with Ganetespib alone, 
the frequencies of γH2AX foci-positive cells were not 
affected immediately, but they did moderately increase at 
later time points (2-24 h), only to return to the baseline at 
48 h after treatment. Combination of hyperthermia with 
Ganetespib led to a further increase of foci-positive cell 
frequencies, especially at later time points (at 16 and 24 
h after treatment). γH2AX is an indirect marker of DSB 
formation and, especially after hyperthermia, it may mark 
sites of other lesions [19]. Therefore, we subsequently 
measured the induction of micronuclei (MN), which are 
a direct consequence of unrepaired DSBs [20] (Figure 
2B). Our results show that hyperthermia alone increased 
MN+ cell frequency at >8 h after treatment, strongly 
suggesting induction of DSBs. In contrast, treatment with 
Ganetespib alone did not significantly affect MN+ cell 
numbers, whereas combinational treatment (hyperthermia 
+ Ganetespib) led to an increased MN induction at later 
time points (at 24 and 48 h), as compared to hyperthermia 
alone (Figure 2B). The frequency of MN+ cells after the 
combinational treatment at 48 h was 3.5-fold (HeLa cells) 
and 6-fold higher (SiHa cells) than in untreated control 
cells. Combined, these results strongly suggest that 
hyperthermia does induce DSBs, probably indirectly, and 
that this effect is potentiated by HSP90 inhibition.
Inhibition of HSP90 enhances radiosensitizing 
and chemosensitizing effects of hyperthermia
Since HSP90 inhibition enhances the inhibitory 
effects of hyperthermia on DSB repair, we investigated 
whether Ganetespib can potentiate cytotoxicity of 
treatment combining various DSB-inducing agents 
(radiation and chemotherapy) with hyperthermia. We 
focused on ionizing radiation (IR), cisplatin, gemcitabine 
and etoposide – chemotherapeutics that are known to 
induce DSBs and that are relevant in clinical cancer 
treatment [21–23]. We performed clonogenic survival 
assays to measure the effects of hyperthermia and/or 
Ganetespib on the cytotoxicity of these agents (Figure 
3). IR directly induces DSBs that are then repaired by 
NHEJ or HR, depending on the cell cycle phase and 
hyperthermia has been shown to sensitize cancer cells 
and tumors to IR [24]. When combined with IR alone, 
Ganetespib did not induce additional cytotoxicity 
(Figure 3B), suggesting that short inhibition of HSP90 is 
insufficient for detectable downregulation of DSB repair. 
However, we detected a statistically significant decrease 
in survival after addition of Ganetespib to IR when it was 
combined with hyperthermia, even at the relatively low 
dose of 2 Gy, in both cell lines (Figure 3B). Cisplatin 
is an effective DNA cross-linking agent and repair of 
cisplatin-induced lesions in replicating cells requires HR 
and nucleotide excision repair [25, 26]. Hyperthermia has 
been reported to be a strong sensitizer to cisplatin [27], 
which is confirmed by our results (Figure 3C). This was 
in contrast to Ganetespib treatment alone, which did not 
enhance cytotoxicity of cisplatin, similar to that of IR. 
However, Ganetespib further enhanced cytotoxicity of 
the cisplatin and hyperthermia combination treatment, at 
least at cisplatin concentrations exceeding 0.9 μM (Figure 
3C). Gemcitabine is a clinically-applied nucleoside 
analog that directly targets HR [28, 29], but its main 
mechanism of action involves inhibition of DNA synthesis 
[30], which can lead to collapse of replication forks and 
induction of DSBs [31]. We found that the cytotoxicity of 
a 24 h incubation period with gemcitabine was generally 
potentiated by hyperthermia, but not by Ganetespib alone 
(Figure 3D). A combination of hyperthermia, gemcitabine 
and Ganetespib, however, significantly decreased cell 
survival, as compared to the hyperthermia + gemcitabine 
combination treatment. This was observed at nearly all 
tested concentrations of gemcitabine, in both HeLa and 
SiHa cells (Figure 3D).
Since our earlier results showed that Ganetespib 
can shorten the time of hyperthermia treatment that is 
required for efficient BRCA2 degradation (Figure 1C), 
we speculated that HSP90 inhibition can also enhance 
radiosensitization by short hyperthermia treatments. 
Remarkably, we indeed found that a 30 min hyperthermia 
+ Ganetespib combination sensitized HeLa and SiHa cells 
to a similar degree as a 60 min exposure to heat alone 
(Figure 3E).
Finally, we tested whether Ganetespib potentiates 
cytotoxicity of etoposide, an inhibitor of topoisomerase 
2 (TOP2), which blocks the TOP2/DNA cleavage 
complexes, leading to DSB formation [32]. Hyperthermia 
did not sensitize SiHa cells to etoposide, and there 
was only a moderate sensitization in HeLa cells, at 
concentrations exceeding 1 μM (Figure 3F). HeLa cells 
were similarly sensitized by addition of Ganetespib alone 
or hyperthermia alone. The combination of Ganetespib 
and hyperthermia did not decrease cell survival in SiHa 
cells and only slightly (and not significantly, p = 0.09) in 
HeLa cells. Combined, these results suggest that chemical 
inhibition of HSP90 can potentiate the cytotoxicity of 
combinational approaches including hyperthermia and 
some, but not all, chemotherapeutic agents that inflict 
DNA damage. At the same time, it is apparent that the 
treatment with Ganetespib alone, at concentrations that 
stimulate cytotoxic effects of hyperthermia, does not 
induce significant toxicity in vitro.
Inhibition of HSP90 combined with 
hyperthermia and IR or cisplatin affects cell 
cycle progression and cell fate
To further explore how HSP90 inhibition enhances 
the cytotoxic effects of hyperthermia in combination 
with radiation and chemotherapy, we recorded time-
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lapse movies of HeLa and SiHa cells after single-agent 
and different combinational treatments. We focused 
on IR and cisplatin because these modalities are often 
combined with hyperthermia for treatment of cervical 
cancer [33, 34] and because our results indicated that 
HSP90 inhibition generally enhances the cytotoxicity of 
these agents when combined with hyperthermia (Figure 
3). All treatment protocols mirrored those used for 
measuring the clonogenic survival (Figure 3A), except 
after refreshment of the medium cells were transferred to a 
live-cell microscope and time-lapse images were recorded 
for up to 96 h. Sample images captured after selected 
treatments are shown in Figure 4A and 4E. We measured 
various parameters related to cell cycle progression, cell 
division and cell fate. First, we determined the average 
duration of the cell cycle under normal conditions, in 
both cell lines (Supplementary Figure 2A). Next, we 
focused on the DNA-damaging agent IR and quantified 
the percentage of treated and control cells that were able 
to enter mitosis within a single or double cell cycle time 
Figure 2: Inhibition of HSP90 enhances induction of DNA damage by hyperthermia (HT). Cells were incubated for 30 min 
with 30 nM Ganetespib (HSP90-i) at 37°C, then for 60 min at 37 or 42°C (HT). Medium was refreshed and cells were incubated at 37°C 
for the indicated time period, fixed and stained for γH2AX (A) and DNA (B). (A) Average percentages of cells with more than 5 γH2AX 
foci after the indicated treatments. (B) The pictures (top panel) show micronuclei (MN)-containing HeLa cells at 48 h after treatments. The 
graphs (bottom panel) show the average frequencies of MN-containing (MN+) cells.
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Figure 3: Inhibition of HSP90 enhances radiosensitizing and chemosensitizing effects of hyperthermia (HT). (A) 
Schematic overview of the treatment schedule for the clonogenic assay, results of which are presented in B-D and F. (B) Normalized 
clonogenic survival after increasing doses of IR alone or combined with HT and/or Ganetespib (HSP90-i). Bar graphs (right-hand panels 
outlined by the dashed lines) show the enlargement of the data points from the 2 Gy dose. (C) Normalized clonogenic survival after 
increasing concentration of cisplatin (Cispl.) alone or combined with HT and/or HSP90-i. At the highest concentration (33 μM) no clones 
were detectable (n.d.). Bar graphs (outlined by dashed lines) show the enlargement of the data points from the 3.3 μM concentration. (D) 
Relative clonogenic survival after increasing concentration of gemcitabine (Gem.) alone or in combination with HT and/or HSP90-i. The 
dotted line indicates the cell survival after treatment with gemcitabine alone. (E) Normalized clonogenic survival of cells incubated at 42°C 
for the indicated period of time, in the presence or absence of HSP90-i and exposed to the indicated dose of IR. (F) Normalized clonogenic 
survival after increasing concentration of etoposide (Etop.) alone or combined with HT and/or HSP90-i. Bar graphs (right-hand side panels 
outlined by dashed lines) show the survival at 3.3 μM concentration of Etoposide.
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(plus two standard deviations) after the treatment (Figure 
4B). We observed that treatment without hyperthermia, 
including exposure to IR, did not significantly affect cell 
cycle progression, since nearly all cells were able to enter 
mitosis within the first 23 h after treatment. In contrast, 
hyperthermia-based treatments reduced the percentage of 
cells that entered mitosis during the first 23 or 48 h. The 
largest reduction was observed after the hyperthermia + 
Ganetespib combination, with or without IR. Additionally, 
hyperthermia-based treatments increased the frequency of 
abnormal first mitoses (Supplementary Figure 2B). These 
differences were not accompanied by an altered duration 
of the cell cycle in cells that successfully completed the 
first mitosis (Figure 4C) but the frequencies of these cells 
were strongly reduced after hyperthermia-based double 
and triple-combinational treatments (Supplementary 
Figure 2D). Furthermore, these treatments generally 
caused considerably increased frequencies of abnormal 
cell division, senescence and apoptosis (Figure 4D). One 
notable exception was the triple-modality treatment of 
SiHa cells, which did induce substantial cell cycle delay 
(Figure 4B) but did not cause abnormalities in those cells 
that were able to successfully divide (Figure 4D).
Treatments with cisplatin showed even stronger 
effects of double and triple modalities involving 
hyperthermia and, interestingly, of the cisplatin + 
Ganetespib double treatment. This was apparent in 
quantification of successful cell divisions (Figure 4F), 
abnormal first mitosis (Supplementary Figure 2C) and 
of cell fate after the second mitosis (Figure 4H). Also 
here, frequencies of these cells were strongly reduced 
after hyperthermia-based double and triple-combinational 
treatments (Supplementary Figure 2E). Similarly to 
experiments involving IR, most combinations, except for 
triple modality in SiHa cells, did not considerably affect 
the length of the first cell cycle after treatment (in those 
cells that were able to successfully divide) (Figure 4G). 
Importantly, the triple combination regimen was clearly 
superior in causing disturbance of the cell cycle and 
mitosis as well as apoptosis and senescence. In conclusion, 
these observations generally confirm that HSP90 
inhibition potentiates cytotoxicity of combinational 
treatments including hyperthermia and cisplatin/IR. 
They also provide further details on how this toxicity is 
manifested in living cells.
Inhibition of HSP90 reduces thermotolerance
Thermotolerance is a hyperthermia-induced state of 
resistance to subsequent hyperthermia treatments, driven 
– at least partially – by expression of HSPs, including 
HSP70 and HSP90 [35]. It has been shown earlier that 
benzoquinone ansamycin inhibitors of Hsp90 can delay 
the recovery from heat stress and suppress some aspects of 
thermotolerance in Drosophila [36]. To establish whether 
Ganetespib can affect these processes in mammalian 
cells, we first evaluated the effects of thermotolerance on 
hyperthermia-mediated reduction of BRCA2 levels. To 
induce thermotolerance, we first treated SiHa and HeLa 
cells for 1 h at 37 or 42°C. 24 h later, we exposed these 
cells to a second hyperthermia treatment, with or without 
Ganetespib, and analyzed levels of BRCA2 by Western 
blotting (Figure 5A). As expected, in control (non-
thermotolerant) cells, hyperthermia reduced BRCA2 levels 
and Ganetespib exacerbated this effect, while hyperthermia 
failed to induce BRCA2 degradation in cells pre-treated at 
42°C, confirming their state of thermotolerance. However, 
addition of a HSP90 inhibitor partially abolished this 
effect, as BRCA2 levels in thermotolerant cells heated 
in the presence of Ganetespib were reduced, albeit not as 
dramatically as in non-thermotolerant cells (Figure 5A).
Thermotolerance was also manifested by a 
significantly reduced ability of hyperthermia to inhibit 
RAD51 foci formation in cells heated 24 h before 
alpha-particle irradiation (Figure 5B, compare bars 5 
and 6 in each panel). However, even in thermotolerant 
cells, RAD51 focus formation was inhibited nearly as 
effectively as in non-thermotolerant cells when they were 
heated in the presence of Ganetespib (Figure 5B, compare 
bars 6 and 8).
Finally, we investigated whether Ganetespib can 
reduce clinically-relevant effects of thermotolerance. We 
observed that hyperthermia-mediated radiosensitization 
of thermotolerant cells was reduced, as compared to their 
non-thermotolerant counterparts, but it could be restored 
by the addition of Ganetespib (Figure 5C). In summary, 
our results demonstrate that HSP90 inhibition can reduce 
multiple aspects of thermotolerance in cervix cancer cell 
lines.
DISCUSSION
Strategies for efficient and targeted inhibition 
of DNA repair can help to improve clinical cancer 
therapies that rely on induction of DNA damage to 
destroy malignant cells. One example of such strategy is 
inhibition of PARP1, a protein involved in repair of SSBs, 
DSBs and in the regulation of the chromatin environment 
[37]. PARP1 inhibitors are used to target HR-deficient 
tumors, while sparing HR-proficient healthy tissues, in 
a reframed synthetic-lethality approach [38, 39]. Our 
previous in vitro and in vivo results suggested that mild 
hyperthermia in clinically-obtainable temperature range 
(41-42.5°C) can be used for on-demand induction of 
HR deficiency in cells and tissues [7] and implied that 
HSP90 inhibition can potentiate this effect. In the current 
study, we further explored this hypothesis and show 
that Ganetespib – a new-generation HSP90 inhibitor – 
enhances hyperthermia-mediated degradation of BRCA2 
and inhibition of HR (Figure 1). These data are in line 
with studies showing that BRCA2 is a client of HSP90 
and that HSP90 inhibition affects BRCA2 stability [40]. 
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Figure 4: Treatments combining inhibition of HSP90 with hyperthermia (HT) and IR/cisplatin affect the cell cycle 
progression and cell fate. (A-D) Cells were preincubated with vehicle or 30 nM Ganetespib (HSP90-i) for 30 min at 37°C, then 
mock-treated or exposed to 2 Gy of γ-radiation and incubated at 37 (control) or 42°C (HT) for one hour. Medium was then refreshed and 
cells were imaged for 96 h at intervals of 15 min. (E-H) Cells were preincubated with vehicle or 30 nM HSP90-i and/or 3.3 μM cisplatin 
(Cispl.) for 30 min at 37°C and then incubated at 37 (control) or 42°C (HT) for 60 min. Medium was refreshed and cells were imaged 
for 96 h at time intervals of 15 min. (A, E) Representative pictures of SiHa and HeLa cells at 48 h after the indicated treatments. (B, F) 
Average percentage of cells that successfully divided within a single (23h for SiHa and 24h for HeLa) or double (48 h) cell cycle time (+ 
two standard deviations). (C, G) Cell cycle times measured as the time between the first and second mitosis after the indicated treatments. 
(D, H) Fate of the daughter cells directly after the second mitosis. The numbers of cells analyzed in each individual treatment/measurement 
group are shown in Supplementary Figure 2.
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In addition to BRCA2, HSP90 manages multiple other 
proteins associated with DNA repair and the stability 
of these factors is affected by inhibition of HSP90 [13, 
40, 41]. This is especially interesting because we have 
shown earlier that DSB repair is shunted to NHEJ upon 
HR inhibition by HT [42] and that protein levels of the 
major NHEJ players DNA-PK and LIGIV increase after 
HT treatment [10, 43]. Since HSP90 inhibition decreases 
DSB-induced phosphorylation of DNA-PK and induces 
degradation of the alternative-NHEJ factor XRCC1 
[13], HSP90 inhibition could limit the functionality of 
NHEJ after HT, further increasing DSB cytotoxicity. The 
combination of a HSP90 inhibitor with hyperthermia 
thus emerges as a self-reinforcing strategy to disable 
DSB repair, creating on-demand conditions of stimulated 
synthetic lethality.
Figure 5: Inhibition of HSP90 reduces thermotolerance. (A) SiHa or HeLa cells were sham-treated or rendered thermotolerant 
by incubation for 1 h at 37 or 42°C (HT), respectively. Some of the treated cell samples were immediately lysed and analyzed by Western 
blotting to confirm the effectiveness of hyperthermia (HT) treatment by analyzing BRCA2 levels (panels marked by ‘WB: day 0’). One 
day later, the remaining samples were subjected to a second HT treatment, in the absence or presence of 30 nM Ganetespib (HSP90-i), 
lysed, and BRCA2 levels were determined by Western blotting (panels marked by ‘WB: day 1’). The experimental design is schematically 
represented in the left-hand panel. ORC2 was used as a loading control. (B) SiHa or HeLa cells were treated as described in (A), except 
immediately after the second HT treatment cells were irradiated using α-particles, fixed 30 min later and immunostained against γH2AX 
and RAD51. Graphs represent the average percentage of cells containing α-particle induced tracks of γH2AX foci that were also positive 
for RAD51. The experimental design is schematically represented in the top panel. (C) Cells were rendered thermotolerant as in (A). 24 h 
later the cells were trypsinized, counted and seeded into 6-well plates. 4 h after seeding, they were incubated for 1 h at 37 or 42°C, in the 
absence or presence of HSP90-i, and exposed to the indicated dose of IR. Normalized clonogenic survival was determined 8 (HeLa) or 12 
(SiHa) days later. The experimental design is schematically represented in the top panel.
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Except for the effects on HR, our results suggest 
induction of DSBs after longer periods of time (16-48 
h) after hyperthermia and – to a larger degree – after 
hyperthermia + Ganetespib treatment (Figure 2). In 
particular, the highly increased MN formation is a strong 
indicator of cells entering mitosis with unrepaired DSBs 
[20]. Induction of MN formation by hyperthermia has 
been reported over three decades ago [44] and confirmed 
more recently [45], but its stimulation by HSP90 
inhibition is a novel observation. The late appearance of 
MN and γH2AX foci suggests that they are not directly 
induced by treatment, but rather arise with the progression 
of the cell cycle. This is in line with the previously 
advanced hypothesis that the induction of DSBs after 
hyperthermia is caused by inhibition of TOP1, leading 
to formation of SSBs [18]. Unrepaired SSBs can then 
derail replication forks and result in DSB formation in 
the next S-phase. Such one-ended DSBs are likely similar 
to those hypothetically induced after PARP1 inhibition. 
Since collapsed replication forks require HR for repair, 
inhibition of HR by hyperthermia contributes to the 
resulting toxicity, but this contribution may be limited by 
the temporary and reversible character of hyperthermia-
mediated HR suppression (Figure 1B).
The observation of enhanced and prolonged 
HR inhibition by hyperthermia + Ganetespib invites 
the combination of stimulated synthetic lethality with 
induction of DSBs in the temporary therapeutic window 
of HR deficiency. This is clearly supported by our 
results showing potentiation of hyperthermia-induced 
radiosensitization and chemosensitization by Ganetespib 
(Figures 3 and 4). Similar to late DSB induction by 
hyperthermia + Ganetespib treatment, clonogenic cell 
death and late effects on the cell cycle and division 
capabilities are observed when treatment is combined 
with DSB-inducing agents including IR, cisplatin and 
gemcitabine. In contrast to these agents, we do not detect 
significant thermal sensitization of cells to the TOP2 
inhibitor etoposide, whether or not Ganetespib is present 
during hyperthermia treatment. This can be explained by 
the previously described inhibitory effects of hyperthermia 
on the formation of TOP2 cleavage complex, which may 
reduce the efficiency of DSB induction and treatment 
cytotoxicity [46].
Our results show at least three different aspects of 
treatments comprising HSP90 inhibition and hyperthermia 
that can be beneficial in cancer treatment (Figure 6). 
First, the treatments produce DSBs in dividing cells 
and likely also cause cytotoxicity by other mechanisms. 
In nearly all experiments, we observed that Ganetespib 
considerably potentiates cell killing by hyperthermia, 
in line with a recent study that reported enhancement of 
the effects of hyperthermia by 17-DMAG [47, 48]. It is 
worth noting that prolonged administration of Ganetespib 
alone can also sensitize cancer cells to radiation and some 
chemotherapeutic drugs [49–51]. Second, the increased 
inhibition of HR (and, potentially, other DNA repair 
mechanisms) by hyperthermia and Ganetespib sensitizes 
Figure 6: Schematic representation of combination therapies involving DNA-damaging agents, HT and HSP90 
inhibitor.
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cells to multiple DSB-inducing agents, indirectly 
increasing their cytotoxicity. Third, Ganetespib could be 
potentially used to reduce thermotolerance and thus enable 
more frequent hyperthermia treatments. The relative 
importance of the first two effects for the final cell killing 
is currently unclear but DSB induction may contribute to 
therapy efficacy in tumor areas where chemotherapeutics 
or radiation do not reach all cancer cells, while sensitizing 
effects could dominate in cells exposed to sufficiently high 
doses of DNA damaging agents.
Importantly for clinical application, our results imply 
that a single, short pulse of Ganetespib, combined with 
hyperthermia, is sufficient for a temporary but considerable 
downregulation of HR (Figure 1) [7]. This approach is 
in conceptual opposition to the long-term application 
of Ganetespib that has been tested in clinical trials [14], 
including the phase III trial of Ganetespib in combination 
with docetaxel which failed in patients with advanced 
non-small cell lung cancer (https://clinicaltrials.gov/ct2/
show/NCT01798485). Long-term exposure to Ganetespib 
has been found to be well tolerated [14] and the single 
application that is required for boosting hyperthermia 
efficacy should be safe in clinical practice. Strategies 
allowing potentiation of the cytotoxic and sensitizing effects 
of hyperthermia can lead to improved therapy outcomes via 
multiple avenues, e.g. by inducing stronger cytotoxicity 
while sparing the non-heated healthy tissues, by allowing 
reduction of the required dose of DNA-damaging agents or 
by rendering hyperthermia treatments effective at decreased 
temperatures or shorter durations. Our study suggests that 
inhibition of HSP90 is one such strategy, with limited 
systemic side-effects, paving the way for rational design of 
improved hyperthermia treatment protocols and for in vivo 
studies involving animal models.
MATERIALS AND METHODS
Cell lines and cell culture
SiHa and HeLa cervical cancer cell lines were 
obtained from the American Type Culture Collection 
(ATCC) and cultured in EMEM medium (Lonza) enriched 
with 10% fetal bovine serum (FBS) and 1% of penicillin/
streptomycin (Gibco, 10000 U/mL). Cells were maintained 
at 37°C, in an atmosphere containing 5% CO2. During 
the experiments with hyperthermia, cells were incubated 
for 65 min at 42°C in an atmosphere containing 5% CO2 
(the medium in the wells needed approx. 5 min to reach 
the target temperature of 42°C). For experiments involving 
α-particles, cells were cultured in custom-made dishes with 
4 μm-thick polypropylene bottom, as described earlier [52].
Chemical agents, hyperthermia treatments and 
irradiation
Cells were treated with the indicated concentrations 
of Ganetespib (STA-9090, Synta Pharmaceuticals), cisplatin 
(cDDP; Platosin®, Pharmachemie), gemcitabine (Actavis) 
and etoposide (Sigma Aldrich). Ganetespib and cisplatin 
were added 30 min before and removed immediately after 
the end of hyperthermia treatments, by washing cells and 
adding fresh medium. Gemcitabine was added 24 h before 
the start of hyperthermia experiments. Hyperthermia was 
applied by partially submerging cell culture dishes in a 
calibrated water bath, at the appropriate CO2 concentration. 
The temperature was monitored by a thermocouple directly 
in cell culture dishes. To allow for temperature increase 
from 37 to 42°C, cells were always incubated 5 min longer 
than what is indicated in the text/figures. In experiments 
involving irradiation, cells were exposed to the indicated 
doses from a 137Cs γ-ray source (~0.5 Gy/min) or from an 
241Am α-particle source. To produce linear tracks of DSBs, 
cells were irradiated through the polypropylene bottom 
of culture dishes for 1 min, with the α-particle source 
positioned under an angle of approximately 45° below the 
bottom of the dish, as described previously [52].
Immunohistochemistry
At the indicated time points after irradiation, cells 
were fixed with 2% paraformaldehyde in PBS for 15 min 
at room temperature. Fixed samples were washed twice 
with PBS and incubated in TNBS (PBS supplemented with 
1% FCS and 0.1% Triton-X100) for 30 min. Samples were 
then incubated with the primary mouse anti-γH2AX (1:100, 
Millipore) and rat anti-Rad51 (1:50) antibodies diluted in 
TNBS for 2 h. After being washed twice in TNBS, samples 
were incubated with the secondary anti-mouse-Cy3 and 
anti-rat-FITC (both 1:100, Jackson ImmunoResearch 
Laboratories) diluted in TNBS, for 1 h. Finally, mounting 
gel containing DAPI (Thermo Scientific) was added and 
samples were covered with glass coverslips. Slides were 
imaged and scored using the wide-field fluorescence 
microscope (DM-RA and DM-RXA, Leica).
Clonogenic assays
24 h before treatment, 2x106 cells were seeded 
into a 10 cm dish. On the day of the experiment, cells 
were trypsinized, counted and plated in triplicates of 
two densities per condition in 6-well plates. After 4 to 
6 h incubation required for cell attachment, cells were 
treated with 30 nM Ganetespib for 90 min with or without 
cisplatin or etoposide. After the first 30 min of incubation 
at 37°C, plates were either transferred to a 42°C water 
bath or were incubated at 37°C for the remaining 65 min. 
In clonogenic survival experiments involving ionizing 
radiation (IR), cells were irradiated after the 30 min 
treatment with Ganetespib, immediately prior to the 
hyperthermia treatment. Directly after hyperthermia, cells 
were washed with PBS and incubated in fresh medium 
for 8 (HeLa) or 13 (SiHa) days. Next, colonies were 
fixed, stained and counted. In experiments involving 
gemcitabine, cells were treated for 24 h, starting directly 
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after plating into 10 cm dishes and until the start of the 
experiment (0 h). A schematic overview of the treatment 
schedules is depicted in Figure 3A.
Time-lapse microscopy
24 h prior to the indicated treatments, cells were 
plated in 6- or 12-well plates at a density of 15,000 or 
7,000 cells per well, respectively. After treatment, cells 
were washed with PBS and fresh medium was added. The 
medium was covered with a layer of mineral oil (Sigma-
Aldrich) to prevent evaporation during imaging. Cells 
were imaged for 96 h, at intervals of 15 min, using a wide-
field phase-contrast microscope (Leica). The cell cycle 
time was defined as the time between the first and second 
successful mitosis observed after treatment; senescence 
was absence of cell division for at least 48 h and abnormal 
mitosis was division that gave rise to abnormal progeny.
Western blotting
Cells were harvested immediately after treatments 
and lysed in Laemmli sample buffer (4% SDS, 20% 
glycerol and 120 mM Tris pH 6.8). Protein levels were 
quantified with the Lowry protein assay. A total of 
50 μg protein supplemented with bromophenol blue 
and β-mercaptoethanol was loaded and separated on a 
NuPage 3-8% Tris-Acetate protein gel (Thermo Fisher 
Scientific). The protein samples were transferred to a 
PVDF membrane, incubated for 1 h in blocking buffer 
at 4°C (PBS with 0.05% Tween (PBS-T) and 3% nonfat 
dry milk) and then overnight with the primary mouse 
anti-BRCA2 (OP95-Ab-1, Merck Millipore), rabbit anti-
cyclin A (C-19, Santa Cruz Biotechnology) or mouse anti-
ORC2 (ab68348, Abcam) antibodies (diluted 1:1000 in 
blocking buffer). The membrane was washed five times 
for 8 min with PBS-T and incubated with the relevant 
secondary antibodies (horseradish peroxidase (HRP)-
conjugated sheep anti-mouse or donkey-anti rabbit IgG, 
both 1:2000 in blocking buffer, Jackson ImmunoResearch 
Laboratories) for 2 h at room temperature. The proteins 
on the membrane were visualized with enhanced 
chemiluminescence (ECL) substrate and imaged with the 
Alliance imager 4.7 (Uvitec).
Data collection and statistics
The unpaired t-test was used for inter-group 
comparisons of the means. Graphs presented in Figure 
4 show results of two independent experiments that 
each included both IR (B-D) and cisplatin (G-I) arms. 
Therefore, the same results obtained from control as 
well as single and double-agent treatments involving 
HT and HSP90-i are shown in both arms. In the case of 
the cisplatin+HSP90-i treatment, n was 1. The numbers 
of cells analyzed in these experiments for each panel of 
Figure 4 (1340 HeLa cells and 1850 SiHa cells in total) 
are presented in Supplementary Figure 2D and 2E. In 
Figure 3C, when 33 μM cisplatin was combined with 
hyperthermia and HSP90-i, n = 1 because no colonies 
could be detected at this concentration in the remaining 
experiments. All other graphs summarize the results of 
at least three independent experiments, with error bars 
indicating standard deviation. Asterisks indicate statistical 
significance with the p-values as follows: * < 0.05, ** < 
0.01, *** < 0.001.
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